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Abstract 39 
Esophageal squamous cell carcinoma (ESCC) is among the leading causes of cancer related 40 
death. Despite extensive efforts in identifying valid cancer prognostic biomarkers, only a very 41 
small number of markers have been identified. Several genetic variants in the 9p21 region have 42 
been identified that are associated with the risk of multiple cancers. Here, we explored the 43 
association of two genetic variants in the 9p21 region, CDKN2A/B, rs10811661 and rs1333049 44 
for the first time in 273 subjects with, or without ESCC. We observed that patients with ESCC 45 
had a higher frequency of a TT genotype for rs10811661 than individuals in the control group, 46 
and this polymorphism was also associated with tumor size. Moreover, a CC genotype for the 47 
rs1333049 polymorphism was associated with a reduced OS of patients with ESCC. In 48 
particular, patients with a CC (rs1333049) genotype had a significantly shorter OS (CC 49 
genotype: 34.5±8.9 months vs. CG+GG: 47.7±5.9 months; p value= 0.03). We have also shown 50 
the association of a novel genetic variant in CDKN2B gene with clinical outcome of ESCC 51 
patients. Further investigations are warranted in a larger population to explore the value of 52 
emerging markers as a risk stratification marker in ESCC. 53 
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57 
Introduction  58 
Esophageal squamous cell carcinoma (ESCC) is the eighth most prevalent cancer globally and 59 
the sixth most common cause of mortality because it is highly aggressive with poor survival rate 60 
(1)(2, 3). Thus, identification of prognostic and predictive biomarkers that can provide an index 61 
of risk of developing ESCC, or help in management of patients at high risk, is warranted. It has 62 
been reported that genetic polymorphisms of specific genes may be involved in esophageal 63 
carcinogenesis (4). Several genes may contributed to ESCC, such as genes involved in folate 64 
metabolism (5), carcinogen metabolism, DNA repair (6) and cell cycle control and oncogenes 65 
(7). The molecular mechanisms underlying the development of ESCC remained unclear. 66 
Recent genome-wide association studies have illustrated that genetics variants in a region located 67 
on chromosome 9p21.3 are associated with multiple cancers (8). Three genes are located in this 68 
region, including cyclin-dependent kinase inhibitors CDKN2A CDKN2B and antisense 69 
noncoding RNA in the INK4 locus (ANRIL), which have been reported to be an important 70 
susceptibility locus for various diseases (8). The expression of the CDKN2B-CDKN2A and 71 
ANRIL genes are co-regulated (9). This locus has been associated with increased risk of 72 
cardiovascular disease and developing several cancers (8). It has been shown that these two 73 
genes are abnormally expressed in gastric cancer and ESCC (8)(10). Several factors can 74 
influence the levels of CDKN2B and CDKN2A gene expression, including deletion, 75 
amplification and genetic variants. Therefore, the aim of the current study was to examine the 76 
associations of 2 genetic variants, rs10811661 and rs1333049 in CDKN2A/B loci with clinical 77 
outcomes of ESCC patients. 78 
Materials and Methods 79 
Patients 80 
Five hundred and ninety individuals with and without ESCC were enrolled from Mashhad 81 
University of Medical Sciences. The ESCC patients were recruited based on the diagnosis of 82 
histologically confirmed locally advanced or metastatic ESCC from Omid Hospital of MUMS 83 
Medical University, during May/2006-August/2014. The control group was recruited as part of 84 
the Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study, as described 85 
previously (11). Individuals had no known history of infectious disease, cancer, myocardial 86 
infarction, nor a family history of stroke, and diabetes mellitus. Nine-mm sections were serially 87 
cut from formalin-fixed paraffin-embedded (FFPE) blocks of the ESCC patients. The study was 88 
approved by local Hospital Ethic Committees of Mashhad University of Medical Sciences. 89 
Genotyping 90 
Genomic DNA was extracted from peripheral blood using QIAamp® DNA Mini-Kit (Qiagen, 91 
San Diego, CA) according to the manufacturer's protocol. The concentration and purity of DNAs 92 
were assessed by the NanoDrop®-1000-Detector (NanoDrop-Technologies, Wilmington, USA). 93 
Genotype analysis of CDKN2A/B-rs10811661 and rs1333049 polymorphisms was carried out 94 
using Taqman®-probes-based assay; PCR reactions were carried out in 12.5 µl total volume, 95 
using 10 ng of DNA in TaqMan® Universal Master Mix with speciﬁc primers and probes (C-96 
901792-10 and C-790057-10; Applied Biosystems Foster City, CA). The ABIPRISM-instrument 97 
equipped with the SDS version-2.0 software was used to evaluate the allelic content of the 98 
samples (11, 12)  99 
 100 
Statistics 101 
Data was analyzed by SPSS-20 software (SPSS Inc., IL, USA). Descriptive statistics of ESCC 102 
patients was reported as the mean and standard deviations (SD) for continuous variables, while 103 
frequencies and percentages were used for categorical variables. Genotype and allele frequencies 104 
of CDKN2A/B rs10811661 polymorphism were assessed for deviation from the Hardy–105 
Weinberg equilibrium (HWE) by using the Pearson χ distribution. The associations between risk 106 
of ESCC for the CC and CT genotypes, relative to the risk genotype TT homozygote under 107 
recessive genetic model were assessed by logistic regression, adjusting for potential confounders, 108 
including; age, sex, body mass index, family history. ESCC risk estimates were expressed as the 109 
odds ratio (OR) and its corresponding 95 % confidence interval (CI). The relationship between 110 
CDKN2A/B rs10811661 polymorphism and clinic pathological features were assessed through 111 
Pearson’s chi-square χ2 test for categorical variables and continuous variables were evaluated 112 
using Student’s t tests. Overall survival (OS) was calculated from the day of treatment start to the 113 
end point (death or censoring) according to Kaplan–Meier method, and compared by log-rank 114 
and Wilcoxon tests. The significant prognostic variables in univariate analysis were included in 115 
Cox’s proportional hazards model. Hazard Ratio (HR) was assessed to investigate the magnitude 116 
and the direction of the effect. All the analyses were two-sided and statistical significance was 117 
set at P<0.05. 118 
Results 119 
Clinicopathological characteristics of patients  120 
Demographic, clinical and genetic characteristics of the population were reported in Table 1. 121 
Among the patients, 48.6% of patients were female, and 51.4% were male with mean age of 122 
58±11yr and BMI of 19.9±5.2. Moreover, in a total of 1.9%, of patients cancer cells grew into 123 
the tissue under the epithelium (T1), in 5.6% of ESCC patients, the cancer cells were into the 124 
thick layer of muscle, a total of 21.5% was in T3 group which cancer grew into the outer layer of 125 
the esophagus, and finally, tumor size in 71% of participants was at T4 status so cancer spread 126 
into vicinity tissues . Also 32.2% of patients the cancer grew into 1 or 2 surrunding lymph node 127 
(N1), while 16.8% of cases had M1(the cancer spread to distant lymph nodes or other tissues) 128 
(Table 1). In order to evaluate whether the patient characteristics might influence clinical 129 
outcome, we analyzed data on PFS and OS according to patients’ clinic-pathological features. 130 
Tumor size, node and metastasis status, and stage were associated with shorter OS and PFS.    131 
Association of the genetic variant with ESCC  132 
In order to explore whether there was an association between CDKN2A/2B Rs10811661 (C/T) 133 
and rs1333049 (C/G) polymorphisms with ESCC, genotyping was performed in all the subjects 134 
using DNA extracted from peripheral bloods. Genotyping was successfully performed in the vast 135 
majority of DNA samples and no discrepancies were found in the samples analyzed in duplicate 136 
(Table 2). As shown in Table 2 and 3, the study included a total of 590 age and sex-matched 137 
subjects (92 ESCC patients and 225 healthy controls for rs1333049 and also 68 ESCC patients 138 
and 205 healthy controls for rs10811661). Table 2 showed the distribution of genotype 139 
frequencies of CDKN2A/B rs10811661 and rs1333049 polymorphisms in the whole population, 140 
which was in the Hardy-Weinberg equilibrium (HWE) (P>0.05). Minor allele frequencies 141 
(MAF) for T and C alleles were 0.16 and 0.3 for rs10811661 and rs1333049. The frequencies of 142 
CC, CT, and TT genotypes for rs10811661 were 8.9, 13.2, and 77.9 %, respectively in the ESCC 143 
group while these frequencies in control group were 4, 25.3, 70.7%, respectively (Table 2).  144 
We then evaluated the genotype distribution of the CDKN2A/B polymorphism with respect to 145 
clinicopathological features of ESCC patients under recessive genetic model (Table 3). This 146 
subgroup analysis showed that 70% of women carried a TT genotype and 80% of patients who 147 
had family history had a TT genotype. Based on the recessive genetic inheritance model, we 148 
found that the TT genotype of the CDKN2A/B polymorphism was associated with larger tumor 149 
size. Moreover, the CDKN2B rs1333049 polymorphism was associated with poor prognosis in 150 
ESCC patients (Figure 1A-B). In particular, patients with CC genotype had a significantly 151 
shorter OS with mean range of 34.5±8.9 months compared to CG+GG genotypes with OS of 152 
47.7±5.9 months (Log Rank p value= 0.038; Figure 1A). Furthermore, the progression free 153 
survival of these cases with TT genotype was 26.9±7.1 months versus CC+CT genotypes with 154 
PFS of 36.8±5.5 months (Figure 1B). 155 
 156 
Discussion 157 
To the best of our knowledge, this is the first study showing the association of a genetic variant 158 
in CDKN2A/B with poor prognosis of patients with ESCC. Our data demonstrated that patients 159 
with a CC genotype had a reduced survival in ESCC patients. This effect might be due to the 160 
function of this gene in the cell-cycle (8, 13-16). It has been shown that the inactivation of 161 
CDKN2A by methylation or ANRIL can suppress the activity of p15/CDKN2B-p16/CDKN2A-162 
p14/ARF encoded by these genes (17). ANRIL indirectly regulates cell proliferation via three 163 
methylations at histon 3 lysine 27 (3meH3K27) in chromosome 9P21, upfront of CDKN2A/B (8) 164 
and recruiting PRC2 and PRC1 complexes to specific loci (18, 19). Several genome-wide 165 
association studies have identified the ANRIL gene as a shared genetic susceptibility locus in 166 
different cancers (18), and may affect ANRIL expression (20). However, the potential 167 
mechanisms underlying the role of these genetic variants in ESCC still remains to be elucidated 168 
(21). Several studies have shown a high ANRIL expression in ESCC patients (22). Furthermore, 169 
inactivation of the CDKN2A gene can be due gene mutations, homozygous deletion and 170 
promotor methylation (23). Frequent homozygous and heterozygous deletions are reported in 171 
CDKN2A and CDKN2B locus in some cancers, including ESCC (24).  172 
***** 173 
Cunnington et al., demonstrated that ANRIL expression was strongly associated with genetic 174 
variants in the CDKN2A/B promoter (9). Suzuki et.al suggested that intragenic point mutations 175 
of CDKN2A and CDKN2B rarely happen in primary esophageal tumors (25). Studies have 176 
reported several mutations in p53 in esophageal carcinoma (26, 27). However a case-control 177 
study conducted on 380 ESC and 380 controls in China population showed no association 178 
between ANRIL rs2151280 T/C with risk of ESC (28). Conversely, Shete and colleagues 179 
revealed that polymorphisms in CDKN2A/B were associated with grade IV and grade II/III 180 
astrocytomas but not with oligo II/III (29). Similarly, Walsh et al., showed that genetic variants 181 
in CDKN2B were associated with low-grade astrocytomas (30) although it was associated with 182 
higher risk for astrocytic tumors in all grades, including glioblastomas (31). Dębniak et.al. 183 
investigated the potential value of CDKN2A as a breast cancer susceptibility gene (32). They 184 
found that the CDKN2A A148T variant may contribute to early-onset breast cancer in Poland 185 
(32). Similarly, Antoniou et al., showed the association of the rs1011970, near 186 
CDKN2A/CDKN2B, with increased risk of breast cancer (33). Moreover, Driver and colleagues 187 
conducted a large-scale case–control study evaluating several polymorphisms within 13 genes 188 
involved in the cell cycle pathway with the risk of breast cancer. This study revealed a 189 
significant relationship between four genetics variants in the region of CDKN2A/2B and breast 190 
cancer risk (34). Another study in a cohort of 120 gastric cancer patients showed the higher 191 
expression of ANRIL in these tumor, which was significantly correlated with a higher TNM 192 
stage and tumor size. Their results suggested that ANRIL expression was an independent 193 
predictor for overall survival (10). Aberrations in CDKN2A gene were also reported with poor 194 
prognosis in renal clear cell carcinoma (35) and ESCC (36-41). In particular, Shen et al., recently 195 
showed that CDKN2A, CDKN2B, FSCN1 and HOMER3 are candidate cancer-associated genes 196 
and may play a tumorigenic role in ESCC. This revealed that a homozygous deletion of 197 
CDKN2A or CDKN2B was associated with lymph node metastasis and the expression of these 198 
genes was lower in dysplasia than in normal esophageal epithelium (36). Another large scale 199 
study analyzed 9p21 SNPs from eight GWASs, including studies of ESCC, gastric cancer, 200 
pancreatic cancer, renal cell carcinoma, lung cancer, breast cancer, bladder cancer and prostate 201 
cancer. They identified several genetic variants in this region associated with the risk of multiple 202 
cancers including ESCC, suggesting that this region may contribute to a shared susceptibility 203 
across different cancer types (38). Gu et al., investigated 203 tagging SNPs of 22 genes on 204 
9p21.3 (19.9-32.8 Mb) in eight case-control studies: thyroid cancer, endometrial cancer, renal 205 
cell carcinoma, colorectal cancer, colorectal adenoma, gastric cardia adenocarcinoma, 206 
osteosarcoma as well as in ESCC (40). They reported that genetic variants in CDKN2A may be 207 
associated with ESCC and several other tumors (40). In line with these observations (37-42), our 208 
data showed an association between CDKN2A/B rs1333049 and clinical outcome of ESCC 209 
patients, supporting further studies in a larger population.  210 
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Fig. 1. Kaplan-Meier survival curves. A) Overall Survival (OS) and B) Progression-Free 347 
Survival (PFS) based on different genotypes of CDKN2B rs1333049 polymorphism. P-values 348 
were calculated with the log-rank test.  349 
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